TScan Therapeutics, Inc. (NASDAQ:TCRX) to Post Q1 2025 Earnings of ($0.26) Per Share, Wedbush Forecasts

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of TScan Therapeutics in a research note issued on Wednesday, April 17th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.26) per share for the quarter. Wedbush currently has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.04) per share. Wedbush also issued estimates for TScan Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS and Q4 2025 earnings at ($0.27) EPS.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.08. The company had revenue of $7.21 million for the quarter, compared to the consensus estimate of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Thursday, March 7th.

TScan Therapeutics Stock Performance

TScan Therapeutics stock opened at $6.92 on Thursday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $331.33 million, a P/E ratio of -3.66 and a beta of 0.90. The stock’s 50 day moving average is $7.04 and its 200 day moving average is $5.64. TScan Therapeutics has a twelve month low of $1.62 and a twelve month high of $9.00.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC bought a new position in TScan Therapeutics in the 4th quarter worth $31,000. Jane Street Group LLC bought a new position in TScan Therapeutics in the 2nd quarter worth $32,000. Renaissance Technologies LLC bought a new stake in TScan Therapeutics during the first quarter valued at about $37,000. Pale Fire Capital SE bought a new stake in TScan Therapeutics during the third quarter valued at about $42,000. Finally, American Century Companies Inc. bought a new stake in TScan Therapeutics during the third quarter valued at about $49,000. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.